Match tier
Listed
Presence
Formerly Arkansas
Last published
2026
Sources
OpenAlex · ORCID
Refreshed
2026-08-16
L
Lirit N. Franks
Researcher
Formerly Arkansas Affiliated with UAMS through 2021; recent publications list University of Utah.
Faculty Researcher
10 h-index
16 pubs
459 cited
Research Areas
Biomedical Subjects
Biography and Research Information
OverviewAI-generated summary
Lirit N. Franks studies cannabinoid receptors, specifically CB1 and CB2, and their role in cellular processes. Franks' research has investigated the expression of these receptors in Ewing sarcoma cell lines, exploring their potential as targets for anti-cancer drug development. Recent publications indicate a focus on how natural and synthetic cannabinoids may reduce the viability of these cancer cells, potentially through non-canonical CB receptor pathways. Franks has a publication record of 16 articles, with 459 citations, and an h-index of 10. Collaborations include work with fellow University of Arkansas for Medical Sciences faculty members Alicja Urbaniak, Paul L. Prather, Amal Shoeib, and Azure L. Yarbrough.
Metrics
- h-index: 10
- Publications: 16
- Citations: 459
Selected Publications
-
Characterization of cannabinoid receptors expressed in Ewing sarcoma TC-71 and A-673 cells as potential targets for anti-cancer drug development (2021)
-
Natural and Synthetic Cannabinoids Reduce Cell Viability of Ewing Sarcoma TC‐71 Cells Potentially via Non‐canonical CB receptors (2021)
-
Reduced Tolerance and Asymmetrical Crosstolerance to Effects of the Indole Quinuclidinone Analog PNR-4-20, a G Protein–Biased Cannabinoid 1 Receptor Agonist in Mice: Comparisons with Δ9-Tetrahydrocannabinol and JWH-018 (2019)
-
Atypical Pharmacodynamic Properties and Metabolic Profile of the Abused Synthetic Cannabinoid AB-PINACA: Potential Contribution to Pronounced Adverse Effects Relative to Δ9-THC (2018)
-
The tamoxifen derivative ridaifen-B is a high affinity selective CB 2 receptor inverse agonist exhibiting anti-inflammatory and anti-osteoclastogenic effects (2018)
-
Characterization of structurally novel G protein biased CB 1 agonists: Implications for drug development (2017)
-
Selective Estrogen Receptor Modulators: Cannabinoid Receptor Inverse Agonists with Differential CB1 and CB2 Selectivity (2016)
-
Tamoxifen Isomers and Metabolites Exhibit Distinct Affinity and Activity at Cannabinoid Receptors: Potential Scaffold for Drug Development (2016)
-
Repeated administration of phytocannabinoid Δ9-THC or synthetic cannabinoids JWH-018 and JWH-073 induces tolerance to hypothermia but not locomotor suppression in mice, and reduces CB1 receptor expression and function in a brain region-specific manner (2015)
-
Characterization of the intrinsic activity for a novel class of cannabinoid receptor ligands: Indole quinuclidine analogs (2014)
-
CB1 and CB2 receptors are novel molecular targets for Tamoxifen and 4OH-Tamoxifen (2013)
-
Human metabolites of synthetic cannabinoids JWH-018 and JWH-073 bind with high affinity and act as potent agonists at cannabinoid type-2 receptors (2013)
-
Design, Synthesis, and Biological Evaluation of Aminoalkylindole Derivatives as Cannabinoid Receptor Ligands with Potential for Treatment of Alcohol Abuse (2013)
-
The omega and omega‐1 monohydroxyl metabolites of the abused K2/Spice synthetic cannabinoids JWH‐018 and JWH‐ 073 bind with high affinity and act as agonists at human cannabinoid 2 receptors (hCB2s) (2012)
-
AM-251 and rimonabant act as direct antagonists at mu-opioid receptors: Implications for opioid/cannabinoid interaction studies (2012)
Collaboration Network
Top Collaborators
Amal Shoeib
University of Arkansas for Medical Sciences
2 shared publications
In database
- Characterization of cannabinoid receptors expressed in Ewing sarcoma TC-71 and A-673 cells as potential targets for anti-cancer drug development
- Natural and Synthetic Cannabinoids Reduce Cell Viability of Ewing Sarcoma TC‐71 Cells Potentially via Non‐canonical CB receptors
Lori L. Hensley
Jacksonville State University (US)
2 shared publications
- Characterization of cannabinoid receptors expressed in Ewing sarcoma TC-71 and A-673 cells as potential targets for anti-cancer drug development
- Natural and Synthetic Cannabinoids Reduce Cell Viability of Ewing Sarcoma TC‐71 Cells Potentially via Non‐canonical CB receptors
Benjamin M. Ford
University of Arkansas for Medical Sciences (US)
2 shared publications
- Characterization of cannabinoid receptors expressed in Ewing sarcoma TC-71 and A-673 cells as potential targets for anti-cancer drug development
- Natural and Synthetic Cannabinoids Reduce Cell Viability of Ewing Sarcoma TC‐71 Cells Potentially via Non‐canonical CB receptors
Alicja Urbaniak
University of Arkansas for Medical Sciences
2 shared publications
In database
- Characterization of cannabinoid receptors expressed in Ewing sarcoma TC-71 and A-673 cells as potential targets for anti-cancer drug development
- Natural and Synthetic Cannabinoids Reduce Cell Viability of Ewing Sarcoma TC‐71 Cells Potentially via Non‐canonical CB receptors
Azure L. Yarbrough
University of Arkansas for Medical Sciences
2 shared publications
In database
- Characterization of cannabinoid receptors expressed in Ewing sarcoma TC-71 and A-673 cells as potential targets for anti-cancer drug development
- Natural and Synthetic Cannabinoids Reduce Cell Viability of Ewing Sarcoma TC‐71 Cells Potentially via Non‐canonical CB receptors
Anna Radomińska‐Pandya
University of Arkansas for Medical Sciences
2 shared publications
In database
- Characterization of cannabinoid receptors expressed in Ewing sarcoma TC-71 and A-673 cells as potential targets for anti-cancer drug development
- Natural and Synthetic Cannabinoids Reduce Cell Viability of Ewing Sarcoma TC‐71 Cells Potentially via Non‐canonical CB receptors
Paul L. Prather
University of Arkansas for Medical Sciences
2 shared publications
In database
- Characterization of cannabinoid receptors expressed in Ewing sarcoma TC-71 and A-673 cells as potential targets for anti-cancer drug development
- Natural and Synthetic Cannabinoids Reduce Cell Viability of Ewing Sarcoma TC‐71 Cells Potentially via Non‐canonical CB receptors
Karol Kacprzak
Adam Mickiewicz University in Poznań (PL)
1 shared publication
- Natural and Synthetic Cannabinoids Reduce Cell Viability of Ewing Sarcoma TC‐71 Cells Potentially via Non‐canonical CB receptors
Lance Benson
University of Arkansas for Medical Sciences (US)
1 shared publication
- Characterization of cannabinoid receptors expressed in Ewing sarcoma TC-71 and A-673 cells as potential targets for anti-cancer drug development
Shengyu Mu
University of Arkansas for Medical Sciences
1 shared publication
In database
- Characterization of cannabinoid receptors expressed in Ewing sarcoma TC-71 and A-673 cells as potential targets for anti-cancer drug development
Similar Researchers
Based on overlapping research topics
Azure L. Yarbrough
University of Arkansas for Medical Sciences
Receptor Mechanisms and Signaling
Cancer-related molecular mechanisms research
Cannabis and Cannabinoid Research
Amal Shoeib
University of Arkansas for Medical Sciences
Receptor Mechanisms and Signaling
Cancer-related molecular mechanisms research
Cannabis and Cannabinoid Research
Paul L. Prather
University of Arkansas for Medical Sciences
Receptor Mechanisms and Signaling
Cannabis and Cannabinoid Research
Pharmacological Effects and Toxicity Studies
Luke Enemark
University of Arkansas for Medical Sciences
Receptor Mechanisms and Signaling
Cancer-related molecular mechanisms research
Pharmacological Effects and Toxicity Studies
Hailey Kristian
University of Arkansas for Medical Sciences
Cancer-related molecular mechanisms research
Pharmacological Effects and Toxicity Studies
Disease Models, Animal
Hui‐Ming Chang
University of Arkansas for Medical Sciences
Receptor Mechanisms and Signaling
Cancer-related molecular mechanisms research
Pharmacological Effects and Toxicity Studies